Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against GeneDx Holdings Corp. and Encourages Investors to Contact the Firm

A class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) alleging the company made false and misleading statements about Fabric Genomics and margin durability. On May 4, 2026, GeneDx revealed a $57.5 million operating loss, lowered 2026 revenue guidance by $65 million, and took a $31.3 million write-down on Fabric Genomics. The stock price declined approximately 50% following the announcement.

07/13/2026, 6:55 PM • GlobeNewswire

WGS INVESTOR DEADLINE: RGRD Law Announces that GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead GeneDx Class Action Lawsuit

GeneDx Holdings Corp. (NASDAQ: WGS) faces a class action lawsuit alleging that executives made false statements about the viability of its Fabric Genomics acquisition. The company revealed significant problems on May 4, 2026, including a drop in adjusted gross margin from 74% to 69%, reduced earnings projections, and a $31.3 million impairment loss, causing the stock to plummet over 49%. Investors with substantial losses have until August 3, 2026 to seek appointment as lead plaintiff.

07/12/2026, 5:00 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) alleging that the company made materially false and misleading statements regarding its business operations. The complaint claims GeneDx misled investors about Fabric Genomics' importance, overstated the durability of reimbursement rates, and failed to disclose that these issues would negatively impact the company's gross margins. Investors who purchased GeneDx securities between April 16, 2025 and May 4, 2026 are encouraged to join the case, with a lead plaintiff deadline of August 3, 2026.

07/12/2026, 12:00 PM • GlobeNewswire

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Insulet Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PODD

Rosen Law Firm has filed class action lawsuits on behalf of investors in Insulet Corporation (PODD), GRAIL, Inc. (GRAL), and GeneDx Holdings Corp. (WGS). The lawsuits allege that defendants made false or misleading statements regarding manufacturing controls, product safety compliance, and regulatory risks. Investors who purchased securities during the specified class periods may be eligible for compensation. The lead plaintiff deadline is August 31, 2026.

07/11/2026, 7:11 PM • GlobeNewswire

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGS

Rosen Law Firm is encouraging investors who purchased GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026 to join a securities class action lawsuit. The lawsuit alleges that GeneDx made false statements regarding the Fabric acquisition's positive impact on the company's financials and operations, when in reality the company knew of significant viability problems that would negatively impact the business. The lead plaintiff deadline is August 3, 2026.

07/11/2026, 6:25 PM • GlobeNewswire

WGS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026

Faruqi & Faruqi, LLP is investigating a federal securities class action against GeneDx Holdings Corp. (NASDAQ: WGS) for allegedly making false and misleading statements about its Fabric Genomics acquisition and overstating the durability of reimbursement rates. On May 4, 2026, GeneDx disclosed missed Q1 results, cut 2026 guidance from $540-555M to $475-490M, and took a $31.3M goodwill impairment charge on the $36.5M Fabric Genomics acquisition. The stock fell 49% ($33.42 per share) on the news. The deadline to seek lead plaintiff appointment is August 3, 2026.

07/11/2026, 8:30 AM • GlobeNewswire

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGS

A securities class action lawsuit has been filed against GeneDx Holdings Corp. for allegedly making false statements about the Fabric acquisition's impact on the company's financials and operations. Investors who purchased GeneDx stock between April 16, 2025 and May 4, 2026 may be entitled to compensation. The lead plaintiff deadline is August 3, 2026.

07/08/2026, 11:02 PM • GlobeNewswire

HBSS Investigates Claims Against GeneDx Holdings (WGS) in Securities Class Action Suit Following Massive Impairment Charge

Hagens Berman is investigating a securities class action lawsuit against GeneDx Holdings (WGS) alleging executives misled investors about the Fabric Genomics acquisition and its synergy potential. The company's stock collapsed 49% on May 5, 2026, following a disastrous Q1 2026 earnings report that included a $31.2 million impairment charge on the Fabric Genomics unit, representing 94% of the acquisition cost. GeneDx also reported a tenfold increase in net loss, missed revenue targets, and slashed 2026 guidance by 12%.

07/08/2026, 2:48 PM • GlobeNewswire

ROSEN, SKILLED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGS

A securities class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) for allegedly making false statements regarding the Fabric acquisition's impact on the company's financials and operational efficiencies. Investors who purchased GeneDx common stock between April 16, 2025 and May 4, 2026 may be entitled to compensation. The deadline to serve as lead plaintiff is August 3, 2026.

07/05/2026, 11:02 PM • GlobeNewswire

WGS INVESTORS: Robbins Geller Rudman & Dowd LLP Announces that GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Robbins Geller Rudman & Dowd LLP announced a securities class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) for allegedly making false statements regarding the Fabric Genomics acquisition. GeneDx revealed significant problems with the acquisition on May 4, 2026, including a drop in adjusted gross margin from 74% to 69%, reduced earnings projections, and a $31.3 million impairment loss, causing the stock to plummet over 49%. Investors with substantial losses can seek appointment as lead plaintiff by August 3, 2026.

07/05/2026, 12:50 PM • GlobeNewswire

CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026

A federal securities class action has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) alleging that the company and its executives made false and misleading statements about the Fabric Genomics acquisition and overstated the durability of reimbursement rates. On May 4, 2026, GeneDx disclosed missed Q1 results, cut 2026 guidance from $540-555 million to $475-490 million, and took a $31.3 million goodwill impairment charge on the Fabric Genomics acquisition purchased for $36.5 million one year prior. The stock fell over 49% on the news. Investors who purchased GeneDx stock between April 16, 2025 and May 4, 2026 may be eligible to participate in the lawsuit, with a deadline of August 3, 2026 to seek lead plaintiff appointment.

07/05/2026, 11:49 AM • GlobeNewswire

GeneDx Holdings Corp. (WGS) Investors: August 3, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP

A securities fraud class action lawsuit has been filed against GeneDx Holdings Corp. for allegedly making material misstatements about the viability of its $51 million acquisition of Fabric Genomics. The company wrote off a $31.3 million impairment loss on the Fabric acquisition in Q1 2026, causing the stock to plunge 49%. Investors who purchased WGS stock between April 16, 2025, and May 4, 2026, have until August 3, 2026, to seek lead plaintiff status.

07/03/2026, 1:05 PM • GlobeNewswire

ROSEN, A TOP-RANKED LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGS

A securities class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) for alleged misrepresentations regarding the Fabric acquisition's impact on the company's business. Investors who purchased GeneDx common stock between April 16, 2025 and May 4, 2026 may be entitled to compensation. The lead plaintiff deadline is August 3, 2026.

07/02/2026, 5:51 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) alleging that the company made materially false and misleading statements regarding its business operations. The complaint claims GeneDx misled investors about Fabric Genomics' importance, overstated the durability of reimbursement rates, and failed to disclose that gross margins would decline. Investors who purchased GeneDx securities between April 16, 2025 and May 4, 2026 are eligible to join the case, with a lead plaintiff deadline of August 3, 2026.

07/01/2026, 12:00 PM • GlobeNewswire

GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

GeneDx Holdings Corp. faces a securities class action lawsuit for failing to disclose material information about its acquisition performance. The company reported a significant drop in adjusted gross margin from 74% to 69%, missed revenue estimates, and disclosed a $31.2 million impairment loss on its Fabric Genomics acquisition. GeneDx shares fell 49.2% on the news. Investors have until August 3, 2026 to file lead plaintiff applications.

06/30/2026, 10:42 PM • GlobeNewswire